NO20056030L - Nye pyridopyraziner og anvendelse derav som kinaseinhibitorer - Google Patents

Nye pyridopyraziner og anvendelse derav som kinaseinhibitorer

Info

Publication number
NO20056030L
NO20056030L NO20056030A NO20056030A NO20056030L NO 20056030 L NO20056030 L NO 20056030L NO 20056030 A NO20056030 A NO 20056030A NO 20056030 A NO20056030 A NO 20056030A NO 20056030 L NO20056030 L NO 20056030L
Authority
NO
Norway
Prior art keywords
kinase inhibitors
novel
pyridopyrazines
novel pyridopyrazines
medicaments
Prior art date
Application number
NO20056030A
Other languages
English (en)
Inventor
Eckhard Guenther
Ulf R Rapp
Eckhard Claus
Irene Seipelt
Ludmilla Wixler
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of NO20056030L publication Critical patent/NO20056030L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Foreliggende oppfinnelse angår nye pyrido[2,3- b]pyrazinderivater med generell formel (I), fremstilling og anvendelse derav som medikamenter, særhg for behandling av malignante og andre sykdommer basert på patologiske celleproliferasjoner.
NO20056030A 2003-05-23 2005-12-19 Nye pyridopyraziner og anvendelse derav som kinaseinhibitorer NO20056030L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10323345A DE10323345A1 (de) 2003-05-23 2003-05-23 Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
PCT/EP2004/005379 WO2004104002A1 (de) 2003-05-23 2004-05-19 Neue pyridopyrazine und deren verwendung als kinase-inhibitoren

Publications (1)

Publication Number Publication Date
NO20056030L true NO20056030L (no) 2006-02-15

Family

ID=33441206

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20056030A NO20056030L (no) 2003-05-23 2005-12-19 Nye pyridopyraziner og anvendelse derav som kinaseinhibitorer

Country Status (17)

Country Link
US (3) US7323468B2 (no)
EP (1) EP1628976A1 (no)
JP (1) JP2007500195A (no)
KR (1) KR20060015283A (no)
CN (2) CN1795195B (no)
AR (1) AR045685A1 (no)
AU (1) AU2004240746B2 (no)
BR (1) BRPI0410632A (no)
CA (1) CA2524948A1 (no)
DE (1) DE10323345A1 (no)
MX (1) MXPA05012592A (no)
NO (1) NO20056030L (no)
RS (2) RS51906B (no)
RU (1) RU2005140378A (no)
TW (1) TW200504062A (no)
WO (1) WO2004104002A1 (no)
ZA (2) ZA200508872B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004022383A1 (de) * 2004-05-06 2005-12-01 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Modulatoren von Kinasen
AU2004240747B2 (en) * 2003-05-23 2008-01-03 Zentaris Gmbh Novel pyridopyrazines and use thereof as kinase modulators
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
US20100132790A1 (en) * 2005-05-09 2010-06-03 Solaris Nanosciences, Inc. Rechargeable Dye Sensitized Solar Cell
CN101356173B (zh) * 2005-11-11 2012-10-31 阿特纳赞塔里斯有限公司 新的吡啶并吡嗪和它们作为激酶调节剂的用途
WO2007054556A1 (de) 2005-11-11 2007-05-18 Æterna Zentaris Gmbh Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
EP1785423A1 (de) * 2005-11-11 2007-05-16 Zentaris GmbH Neue Pyridopyrazine und deren Verwendung als Modulatoren von Kinasen
EP1790342A1 (de) * 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
EP1990342A1 (en) * 2007-05-10 2008-11-12 AEterna Zentaris GmbH Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2508184A1 (en) 2011-04-06 2012-10-10 Æterna Zentaris GmbH Pyridopyrazine derivatives and their use
WO2012167423A1 (en) * 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
MA39784B1 (fr) 2014-03-26 2021-03-31 Astex Therapeutics Ltd Combinaisons des inhibiteurs du fgfr et du cmet destinées au traitement du cancer
RU2715893C2 (ru) 2014-03-26 2020-03-04 Астекс Терапьютикс Лтд Комбинации ингибитора fgfr и ингибитора igf1r
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
HRP20220012T1 (hr) 2015-09-23 2022-04-01 Janssen Pharmaceutica Nv Bi-heteroaril supstituirani 1,4-benzodiazepini i njihova upotreba za liječenje raka
MX2018003563A (es) 2015-09-23 2018-06-18 Janssen Pharmaceutica Nv Nuevos compuestos.

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5053394A (no) 1973-09-20 1975-05-12
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
TW274550B (no) 1992-09-26 1996-04-21 Hoechst Ag
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
UA71555C2 (en) * 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
BR0212510A (pt) * 2001-09-14 2004-08-24 Methylgene Inc Inibidor de histona desacetilase, composto e composição
US7223738B2 (en) 2002-04-08 2007-05-29 Merck & Co., Inc. Inhibitors of Akt activity
US20060142178A1 (en) 2002-04-08 2006-06-29 Barnett Stanley F Method of treating cancer
JP4451136B2 (ja) 2002-04-08 2010-04-14 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性阻害薬
JP4903997B2 (ja) 2002-07-02 2012-03-28 サザン リサーチ インスティチュート ＦｔｓＺの阻害剤およびそれらの用途
KR20120032574A (ko) 2002-10-03 2012-04-05 탈자진 인코포레이티드 혈관항상성 유지제 및 그의 사용 방법
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
AU2003270701B2 (en) * 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
DE10323345A1 (de) 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
AU2004259269A1 (en) 2003-07-18 2005-02-03 Basf Aktiengesellschaft Aryl-condensed 3-arylpyridine compounds and use thereof for controlling pathogenic fungi
WO2005056825A1 (en) 2003-12-05 2005-06-23 Board Of Regents, The University Of Texas System Screening for modulators of mekk2 and mekk3
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
DE102004017932A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
JP4903133B2 (ja) 2004-04-30 2012-03-28 ジェネンテック，インコーポレイティド ヘッジホッグシグナル伝達のキノキサリン阻害剤
GB0413953D0 (en) 2004-06-22 2004-07-28 Syngenta Participations Ag Chemical compounds
GB0413955D0 (en) 2004-06-22 2004-07-28 Syngenta Participations Ag Chemical compounds
TW200621251A (en) 2004-10-12 2006-07-01 Neurogen Corp Substituted biaryl quinolin-4-ylamine analogues
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
JP2006137723A (ja) 2004-11-15 2006-06-01 Kyowa Hakko Kogyo Co Ltd スルホンアミド誘導体
WO2006059103A2 (en) 2004-12-03 2006-06-08 Peakdale Molecular Limited Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products
US20070293456A9 (en) 2004-12-30 2007-12-20 Anthony Hayford Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
WO2006076646A2 (en) 2005-01-14 2006-07-20 Neurogen Corporation Heteroaryl substituted quinolin-4-ylamine analogues
US7709472B2 (en) 2005-01-25 2010-05-04 Glaxo Group Limited Antibacterial agents
JP2008528588A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
WO2006081264A1 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
CA2594998A1 (en) 2005-01-25 2006-08-03 Neurogen Corporation Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues
JP2008528586A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer

Also Published As

Publication number Publication date
WO2004104002A1 (de) 2004-12-02
CA2524948A1 (en) 2004-12-02
US20050032803A1 (en) 2005-02-10
AR045685A1 (es) 2005-11-09
ZA200508633B (en) 2006-07-26
US7323468B2 (en) 2008-01-29
AU2004240746B2 (en) 2007-05-31
RU2005140378A (ru) 2007-06-27
JP2007500195A (ja) 2007-01-11
US8193186B2 (en) 2012-06-05
US20080113991A1 (en) 2008-05-15
AU2004240746A1 (en) 2004-12-02
RS20050864A (en) 2008-04-04
CN1795195B (zh) 2010-04-21
DE10323345A1 (de) 2004-12-16
EP1628976A1 (de) 2006-03-01
BRPI0410632A (pt) 2006-06-13
CN1795195A (zh) 2006-06-28
US20070275972A1 (en) 2007-11-29
ZA200508872B (en) 2006-07-26
RS20050876A (en) 2008-04-04
MXPA05012592A (es) 2006-02-08
TW200504062A (en) 2005-02-01
CN1795194A (zh) 2006-06-28
RS51906B (sr) 2012-02-29
KR20060015283A (ko) 2006-02-16

Similar Documents

Publication Publication Date Title
NO20056030L (no) Nye pyridopyraziner og anvendelse derav som kinaseinhibitorer
NO20056032L (no) Nye pyridopyraziner og anvendelse derav som kinasemodulatorer
NO20082511L (no) Nye pyridopyraziner og deres anvendelse som kinasemodulatorer
RS105204A (en) Substituted 3-amino-thieno/2,3-b/pyridine- 2-carboxylic acid amide compounds and processes for preparing and their uses
ATE365742T1 (de) 4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren
MY132106A (en) New pyridazin-3(2h)-one derivatives
NO20063821L (no) Kinolinderivater for anvendelse som mykobakterielle inhibitorer
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
NO330981B1 (no) Indol- eller benzimidazolderivater for modulering av IkB-kinase, fremgangsmate for fremstilling av disse, legemiddel og anvendelse av forbindelsene
NO20054085L (no) Substituerte heksahydropyrazino [1,2-a]pyrimidin-4,7-dionderivater, fremgangsmater for fremstilling og anvendelse derav som medikamenter
NO20054208L (no) Nitrogen-substituerte heksahydropyrazino[1,2-a]pyrimidin-4,7-dionderivater, fremgangsmater for fremstilling og anvendelse derav som medikamenter
NO20092033L (no) Nye forbindelser
TNSN05194A1 (en) Substituted n-arylheterocycles, method for production and use thereof as medicaments
MY139303A (en) Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
MXPA05012466A (es) Derivados de quinolina como inhibidores de fosfodiesterasa.
NO20054726L (no) 2, 4-di(fenylamino)pyrimidiner anvendelige ved behandling av neoplastiske sykdommer, inflammasjons- og immunsystemforstyrrelser
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
NO20061363L (no) Pyrazolo- og imidazo- pyrimidinderivater
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
BR0307574A (pt) Derivados de nicotinamida úteis como inibidores de pde4
NO20080418L (no) Pyrido[2,3-D]pyrimidiriderivater, fremgangsmate for fremstilling derav og terapeutisk anvendelse av samme
EA200401319A1 (ru) Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине
ATE389655T1 (de) Pyrimidinderivate
IL166057A0 (en) Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments